Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study.
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead181
Abstract: OBJECTIVES To evaluate enthesitis treatment response, including time to resolution and data from multiple enthesitis instruments, in patients with psoriatic arthritis (PsA) treated with secukinumab or adalimumab for 52 weeks. METHODS In this post hoc analysis… read more here.
Keywords: lei sparcc; secukinumab adalimumab; resolution; adalimumab ... See more keywords
A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.13635
Abstract: To compare the cost‐effectiveness of secukinumab vs adalimumab at 1 and 2 years of treatment in patients with ankylosing spondylitis (AS) by analyzing the cost per responder reported in randomized controlled trials (RCTs) from the… read more here.
Keywords: cost per; korean perspective; ankylosing spondylitis; per responder ... See more keywords